David Shaw’s Dianthus Therapeutics DNTH Stock Holding History

David Shaw’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.18M	Sell	42,928 -106,681	-71%	-$9.32M	﹤0.01%	2555
2026 Q1	$12.6M	Sell	149,609 -5,069	-3%	-$294K	0.01%	1453
2025 Q4	$6.37M	Buy	154,678 +123,064	+389%	+$4.77M	﹤0.01%	2108
2025 Q3	$1.24M	Buy	+31,614	New	+$808K	﹤0.01%	3322
2022 Q3	–	Sell	-3,314	Closed	-$64K	–	5260
2022 Q2	$64K	Buy	3,314 +2,190	+195%	+$54.1K	﹤0.01%	4803
2022 Q1	$52K	Buy	+1,124	New	+$61.4K	﹤0.01%	5135
2018 Q4	–	Sell	-1,116	Closed	-$214K	–	3799
2018 Q3	$214K	Buy	+1,116	New	+$235K	﹤0.01%	3516

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

David Shaw's DNTH Position: Q2 2026 in Review

David Shaw reduced its Dianthus Therapeutics (DNTH) stake by 71% in Q2 2026, selling an estimated $9.32M and leaving 42,928 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2555.

David Shaw first reported a position in DNTH in Q3 2018 and has held it in 7 quarters since. The position peaked at $12.6M in Q1 2026. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

David Shaw held 42,928 shares of Dianthus Therapeutics worth $4.18M as of Q2 2026.
David Shaw sold 106,681 Dianthus Therapeutics shares in Q2 2026, an estimated $9.32M.
Dianthus Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2555 holding.
David Shaw first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 7 quarters since.
David Shaw's Dianthus Therapeutics position peaked at $12.6M in Q1 2026.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.